Deals, Diagnostics

MGC Diagnostics to acquire Medisoft.

Posted on 14 July 2014

Tags: ,

MGC Diagnostics has completed a stock purchase agreement to acquire Medisoft.

Medisoft is a Sorinnes, Belgium headquartered, privately held manufacturer of market-leading cardiorespiratory diagnostic products.

The Company plans to close the transaction on August 1, 2014.

Medisoft has served the cardiorespiratory diagnostics market since 1979 and had 2013 revenues of approximately 4.7 million ($6.4 million).

Under the Stock Purchase Agreement, MGC Diagnostics will acquire Medisoft for cash consideration of 5.8 million ($7.9 million) and three-year warrants to purchase 1.0 million ($1.4 million) of MGCD common stock.

Of the 5.8 million in cash consideration, approximately 4.1 million ($5.6 million) will be paid to Medisoft shareholders and approximately 1.7 million ($2.3 million) will be used to pay off existing Medisoft debt.


Report: Diagnostics Partnering Terms and Agreements

Browse: Complete Current Partnering report catalogue

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply